Wells Fargo's analyst, Brandon Couillard, has maintained an "Underweight" rating on Mesa Laboratories (MLAB, Financial), while lowering the price target from $120.00 to $100.00. The adjusted price target reflects a decrease of 16.67%.
This decision was announced on May 30, 2025. According to the report, the rating remains unchanged from the prior "Underweight" status, indicating a consistent outlook from Wells Fargo on the stock's performance in the market.
The currency for the price target remains in USD, with the current price target being $100.00. Stockholders and market watchers are advised to consider this latest adjustment from Wells Fargo when making investment decisions regarding Mesa Laboratories (MLAB, Financial).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Mesa Laboratories Inc (MLAB, Financial) is $135.00 with a high estimate of $160.00 and a low estimate of $100.00. The average target implies an upside of 31.13% from the current price of $102.95. More detailed estimate data can be found on the Mesa Laboratories Inc (MLAB) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Mesa Laboratories Inc's (MLAB, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Mesa Laboratories Inc (MLAB, Financial) in one year is $153.58, suggesting a upside of 49.18% from the current price of $102.95. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Mesa Laboratories Inc (MLAB) Summary page.
